Exelixis (EXEL) Cash & Current Investments (2010 - 2026)
Exelixis' (EXEL) quarterly Cash & Current Investments came in at $777.2 million in Q2 2026, down 24.64% year-on-year from $1.0 billion in Q2 2025, and down 26.62% quarter-over-quarter from $1.1 billion in Q1 2026.
Exelixis (EXEL) Cash & Current Investments (2010 - 2026) Analysis & Trends
Exelixis' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $777.2 million for Q2 2026.
- On a quarterly basis, Cash & Current Investments fell 24.64% year-over-year to $777.2 million in Q2 2026; TTM through Apr 2026 was $777.2 million, a 24.64% decrease from a year earlier, with the FY2026 full-year figure at $1.1 billion, down 4.7% from the prior year.
- Cash & Current Investments retreated to $777.2 million in Q2 2026 per EXEL's latest filing, from $1.1 billion in the prior quarter.
- Across five years, Cash & Current Investments topped out at $1.6 billion in Q2 2022 and bottomed at $777.2 million in Q2 2026.
- The 5-year median for Cash & Current Investments is $1.1 billion (2023), against an average of $1.2 billion.
- Across the five-year window, Cash & Current Investments soared 32.46% in 2022 and slipped 28.68% in 2023, its largest moves.
- Year by year, Cash & Current Investments stood at $1.3 billion in 2022, then decreased by 23.93% to $995.3 million in 2023, then climbed by 19.48% to $1.2 billion in 2024, then slipped by 16.87% to $988.5 million in 2025, then dropped by 21.38% to $777.2 million in 2026.
- Per Business Quant, the three latest EXEL Cash & Current Investments figures stand at $777.2 million (Q2 2026), $1.1 billion (Q1 2026), and $988.5 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.27 Bn | 467.47 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 122.18 Bn | 114.93 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.32 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Exelixis | 14.52 Bn | 13.74 Bn | 590.86 Mn | 777.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 777.21 Mn |
| Jan 2, 2026 | 1.06 Bn |
| Oct 3, 2025 | 988.54 Mn |
| Jul 4, 2025 | 791.10 Mn |
| Apr 4, 2025 | 1.03 Bn |
| Jan 3, 2025 | 1.11 Bn |
| Sep 27, 2024 | 1.19 Bn |
| Jun 28, 2024 | 1.00 Bn |
| Mar 29, 2024 | 963.26 Mn |
| Dec 29, 2023 | 995.30 Mn |
| Sep 29, 2023 | 1.10 Bn |
| Jun 30, 2023 | 1.27 Bn |
| Mar 31, 2023 | 1.31 Bn |
| Dec 30, 2022 | 1.31 Bn |
| Sep 30, 2022 | 1.55 Bn |
| Jul 1, 2022 | 1.53 Bn |
| Apr 1, 2022 | 1.57 Bn |
| Dec 31, 2021 | 1.47 Bn |
| Oct 1, 2021 | 1.40 Bn |
| Jul 2, 2021 | 1.35 Bn |